


## PERSONAL INFORMATION

**Bastianina Canu** +39 3484558656 Bastianina.canu@iqvia.com

## PREFERRED JOB

Dedicated line Manager

## WORK EXPERIENCE

09/2022 - Present    Dedicated Line Manager (DLM)  
*IQVIA*

As DLM responsible to manage staff in accordance with organization's policies and applicable regulations. Responsibilities include employee relations issues and resolving problems, appraising performance discussion and guiding professional development. Provide oversight for the execution of the training plan, SOP review and mentored training experiences, as applicable. Ensure that staff has the proper materials, systems access and training to complete job responsibilities. Participate in the allocation of resources to clinical research projects by assigning staff to clinical studies that are appropriate to their experience and training. Identify quality risks and issues and create appropriate corrective action plans to prevent or correct deficiencies in performance of staff.

Manage the quality of assigned staff's clinical work through regular review and evaluation of work product. Ensure that staff are meeting defined workload and quality metrics through regular review and reporting of findings as outlined by clinical operations management.

01/2012 – 08/2022    Senior CRA (Clinical Research Associate)  
*IQVIA*

Work in Clinical Research as a CRA since January 2012. Attended a one Year Master in Clinical Research at the University of Pisa and then 2 week class room training at the CRA School in Quintiles.

Background in all clinical monitoring activities such as onsite visits, contact and follow up with investigators, assessment of patient safety, data quality, adherence to agreed protocol SOPs and study documentation (on site and in house) management. Main Therapeutic Areas deepened: Cardiology

(Thromboembolism of Vein), Oncology (Breast Cancer, Leukemia, Malignant Melanoma, Basal Cell Carcinoma, NSCLC, SCLC, SCCHN, Mantle Cell Lymphoma) and Infectious Disease (Flu).

Therapeutic area and specific project training. Main contact with sites, performing site selection visits, initiation visits, monitoring visits, close out visits, evaluations and ensuring patient safety, data quality, adherence to the protocol and agreed SOPs. Compliance with overall study timelines to maintain recruitment progress, data cleaning and appropriate IMP management. Create, distribute and maintain all relevant study documentation.

Educate and train site and study staff regarding conduct and the management of sponsored studies, including assurance of regulatory and ICH/ GCP compliance.

MENTOR/BUDDY to Junior o Trainee CRA with excellent results and SME ICF.

2007 - 12/ 2011

Preclinical Research

*University of Pisa*

The main research activity has been focused on chemotherapeutic drug and antiangiogenic drug research, including *in vitro* and *in vivo* experimental settings, and clinical pharmacology of chemotherapeutic and antiangiogenic therapies. Involved in the pharmacokinetic and pharmacodynamic study of metronomic chemotherapy in both preclinical and clinical trials, in surrogate markers for antiangiogenic therapies such as monoclonal antibodies and tyrosine kinase inhibitors and in the pharmacogenetic of drugs used in the treatment of prostate, breast and colorectal cancer.

Main duties: Providing *invitro* (cell and tissues) and *in vivo* (animals) research systems to test interaction between the drug and the biological system to predict what effect the drug might have on humans; perform animal surgeries, compound administration, clinical monitoring. Designing, planning and conducting controlled experiments to improve the understanding of a compound's activity; drawing up proposals for future developmental tests; applying and developing the results of research to work through a variety of applications, such as new products, processes, techniques and practices; using high technology measuring systems and to analyse and interpret complex data.

## EDUCATION AND TRAINING

---

- 07/1996 High scientific school  
Istituto Scientifico E. Fermi, Italy
- 03/2004 Degree –Biology  
University of Cagliari, Italy

- 12/2010 PhD “Medical Physiopathology and Pharmacology”
- 12/2011 Master “Clinical research“  
University of Pisa, Italy
- 12/2013 Graduate school “Pharmacology“  
University of Pisa

PERSONAL SKILLS

Mother tongue(s) Italian

Other language(s)

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	BUSINESS LEVEL	BUSINESS LEVEL	BUSINESS LEVEL	BUSINESS LEVEL	BUSINESS LEVEL
	Replace with name of language certificate. Enter level if known.				
French	Basic	Basic	Basic	Basic	Basic
	Replace with name of language certificate. Enter level if known.				

**Communication skills** Excellent written and verbal communication skills.  
 Confident, articulate, and professional speaking abilities (with experience)  
 Empathic listener and persuasive speaker.  
 Creative writing or factual.  
 Speaking in public, to groups, or via electronic media.  
 Excellent presentation and negotiation skills.

**Organisational / Managerial skills** Collaboration and Client Focus are competencies clearly developed.  
 Established and maintained relationships between clients and researchers to ensure a productive and cooperative research environment.  
 Good Innovation competency. Ability to propose improvement opportunities and to find a new way to work (smarter and easier) to share with clients and teams.  
 Ability to interface effectively with all levels of staff.  
 Ability to prepare and maintain accurate records.  
 Strong organizational and time management skills.  
 Ability to outstand conflict resolution skills, as well as the ability to anticipate challenges and appropriate solutions.

Digital skills

Information processing	Communication	Content creation	Safety	Problem solving
Enter level	Enter level	Enter level	Enter level	Enter level
INDEP.USER	INDEP. USER	INDEP. USER	INDEP. USER	INDEP. USER

Driving licence

B Driving License, 2006

## Publications

Antiproliferative and Proapoptotic Activity of Sunitinib on Endothelial and Anaplastic Thyroid Cancer Cells via Inhibition of Akt and ERK1/2 Phosphorylation and by Down-Regulation of Cyclin-D1. Di Desidero T, Fioravanti A, Orlandi P, Canu B, Giannini R, Borrelli N, Man S, Xu P, Fontanini G, Basolo F, Kerbel RS, Francia G, Danesi R, Bocci G. *J Clin Endocrinol Metab.* 2013 Aug 22.

Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells, Bocci G, Fioravanti A, La Motta C, Orlandi P, Canu B, Di Desidero T, Mugnaini L, Sartini S, Cosconati S, Frati R, Antonelli A, Berti P, Miccoli P, Da Settimo F, Danesi R., *Biochem Pharmacol.* 2011 Jun 1;81(11):1309-16. doi: 10.1016/j.bcp.2011.03.022. Epub 2011 Apr 1.

Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers, Allegrini G, Di Desidero T, Barletta MT, Fioravanti A, Orlandi P, Canu B, Chericoni S, Loupakis F, Di Paolo A, Masi G, Fontana A, Lucchesi S, Arrighi G, Giusiani M, Ciarlo A, Brandi G, Danesi R, Kerbel RS, Falcone A, Bocci G., *Angiogenesis.* 2012 Mar 2

EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan. Loupakis F, Cremolini C, Fioravanti A, Orlandi P, Salvatore L, Masi G, Schirripa M, Di Desidero T, Antoniotti C, Canu B, Faviana P, Sensi E, Lupi C, Fontanini G, Basolo F, Di Paolo A, Danesi R, Falcone A, Bocci G. *Target Oncol.* 2013 Jul 3

First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study, Marchetti V, Giorgi M, Fioravanti A, Finotello R, Citi S, Canu B, Orlandi P, Di Desidero T, Danesi R, Bocci G., *Invest New Drugs.* 2011 Apr 21

Irinotecan synergistically enhances the antiangiogenic and antitumor activity of axitinib in vitro and in vivo, Bastianina Canu, Anna Fioravanti, Paola Orlandi, Teresa Di Desidero, Greta Ali, Gabriella Fontanini, Antonello Di Paolo, Mario Del Tacca, Romano Danesi and Guido Bocci, *Neoplasia* 2010

Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. Fioravanti A, Canu B, Ali G, Orlandi P, Allegrini G, Di Desidero T, Emmenegger U, Fontanini G, Danesi R, Del Tacca M, Falcone A, Bocci G., *Eur J Pharmacol.* 2009 Oct 1;619(1-3):8-14. Epub 2009 Aug 18.

The -604AA VEGFR-2 genotype frequency is significantly lower in age-related macular degeneration patients, Stefano Lazzeri MD, Paola Orlandi PhD, Michele Figus, MD, Anna Fioravanti PhD, Elisa Cascio PharmD, Teresa Di Desidero PharmD, Bastianina Canu PhD, Romano Danesi MD PhD, Marco Nardi MD, Guido Bocci MD PhD, IOVS 2010

VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide. Orlandi P, Fontana A, Fioravanti A, Di Desidero T, Galli L, Derosa L, Canu B, Marconcini R, Biasco E, Solini A, Francia G, Danesi R, Falcone A, Bocci G. *Br J Cancer*. 2013 Aug 20;109(4):957-64. doi: 10.1038/bjc.2013.398. Epub 2013 Jul 16.

Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells. Bocci G, Fioravanti A, La Motta C, Orlandi P, Canu B, Di Desidero T, Mugnaini L, Sartini S, Cosconati S, Frati R, Antonelli A, Berti P, Miccoli P, Da Settimo F, Danesi R. *Biochem Pharmacol*. 2011 Jun 1;81(11):1309-16. doi: 10.1016/j.bcp.2011.03.022. Epub 2011 Apr 1.

The rs2071559 AA VEGFR-2 genotype frequency is significantly lower in neovascular age-related macular degeneration patients. Lazzeri S, Orlandi P, Figus M, Fioravanti A, Cascio E, Di Desidero T, Agosta E, Canu B, Sartini MS, Danesi R, Nardi M, Bocci G. *ScientificWorldJournal*. 2012;2012:420190. doi: 10.1100/2012/420190. Epub 2012 Aug 1.

A new biometric tool for three-dimensional subcutaneous tumor scanning in mice. Bocci G, Buffa F, Canu B, Concu R, Fioravanti A, Orlandi P, Pisanu T. *In Vivo*. 2014 Jan-Feb;28(1):75-80.

Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer, Fotios Loupakis, Chiara Cremolini, Anna Fioravanti, Paola Orlandi, Lisa Salvatore, Gianluca Masi, Teresa Di Desidero, Bastianina Canu, Marta Schirripa, Paolo Frumento, Antonello di Paolo, Romano Danesi, Alfredo Falcone, Guido Bocci, *British journal of cancer* 2010.